Stockwinners Market Radar for October 09, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:23 EDT Cathie Wood's ARK Investment bought 144K shares of Intellia Therapeutics today

18:03 EDT Mistras CEO Dennis Bertolotti to depart, Manuel Stamatakis named interim CEO - Mistras announced a series of key leadership transitions that promise to guide the company into its next phase of growth and innovation. Dr. Sotirios Vahaviolos is retiring as Executive Chairman after nearly 40 years of exceptional leadership and has been appointed Chairman Emeritus while remaining an active member of the Board of Directors. Succeeding him, the Board has appointed Manuel Stamatakis as Chairman of the Board. Dennis Bertolotti will be departing Mistras as its CEO, and the Board has asked Stamatakis to serve as the Interim CEO until a successor CEO is found. James Forese, the current Chairman of the Audit Committee, has been named Lead Director and Chairman of the Corporate Governance Committee.

17:20 EDT Hyatt to replace National Instruments in S&P 400 at open on 10/12 - Emerson Electric (EMR) is acquiring National Instruments (NATI) in a deal expected to be completed soon pending final conditions.

17:06 EDT Associated Capital reports preliminary Q3 book value per share $41.35-$41.55 - Associated Capital Group announced a preliminary range for its third quarter book value of $41.35 to $41.55 per share. This compares to $41.41 per share at June 30, 2023, $40.48 per share at December 31, 2022 and $39.96 per share at September 30, 2022. Assets under management were $1.59B at September 30, 2023, compared to $1.75B at September 30, 2022.

17:02 EDT Oceaneering announces Petrobras drill pipe riser systems contract - Oceaneering International (OII) announced that one of its wholly owned subsidiaries, Marine Production Systems do Brasil Ltda., has secured a five-year contract from Petroleo Brasileiro S.A. (PBR) for the operation of three existing drill pipe riser systems to support intervention and completion operations in Brazil. Petrobras also has the option to add a fourth DPR system by notifying Oceaneering prior to mid-December 2023. The contract value could be worth up to $75 million in revenue during the five-year contract period. Under the terms of the contract, Oceaneering will continue to provide Petrobras with services utilizing three existing drill pipe riser systems with installation workover control systems, or IWOCS, along with project management, engineering and support services. The company will be replacing the umbilicals on the existing systems in 2024. The replacement umbilicals are planned to be manufactured at Oceaneering's facility in Niteroi, Brazil. Field operations under the contract are anticipated to commence when the current contract expires, or 18 months after award. Should Petrobras elect to add a fourth system, Oceaneering will have an additional 18 months to build the system, which would be expected to go on hire in June 2025.

16:46 EDT Supernus resubmits NDA for SPN-830 apomorphine infusion device - Supernus Pharmaceuticals announced it has resubmitted its New Drug Application for its apomorphine infusion device for the continuous treatment of motor fluctuations in Parkinson's disease. Working closely with the U.S. Food and Drug Administration, Supernus believes it has addressed the FDA's questions related to a Complete Response Letter issued in October 2022 for the SPN-830 New Drug Application. The CRL required additional information and analysis related to the infusion device and drug product across several areas of the NDA. In addition, the FDA mentioned at the time that approval of the NDA required inspections that could not be completed in a timely manner due to COVID-19 travel restrictions. The CRL did not request additional efficacy and safety clinical studies. Supernus will continue to work closely with the FDA as it reviews the SPN-830 NDA. "SPN-830 represents a novel and less invasive therapy approach for PD patients who are seeking a convenient option in the form of a continuous subcutaneous infusion of apomorphine," said Jack Khattar, President and CEO of Supernus. "We look forward to continuing our effort with the FDA throughout the NDA review process to bring a promising alternative to patients and their families."

16:34 EDT Unity down 1% at $29.40 after announcing immediate CEO retirement

16:32 EDT Poseida Therapeutics names Kristin Yarema, Ph.D as CEO, effective Jan 1, 2024 - Poseida Therapeutics (PSTX) announced the appointment of Mark Gergen as Executive Chairman and the transition of Kristin Yarema, Ph.D., currently President, Cell Therapy, to the role of President and CEO, each expected to be effective January 1, 2024. Now in her third decade in the biopharmaceutical industry, Dr. Yarema joined the company as President of Cell Therapy in April 2023, bringing extensive biopharmaceutical experience in oncology and allogeneic T cell immunotherapy. Prior to Poseida she served as Chief Commercial Officer at Atara Biotherapeutics (ATRA) where she led the commercialization of EBVALLO, which became the world's first marketed allogeneic T cell therapy after receiving regulatory approval in Europe for the treatment of a rare lymphoma.

16:31 EDT Unity CEO John Riccitiello to retire - Unity "announced that John Riccitiello will retire as President, CEO, Chairman and a member of the Company's Board of Directors, effective immediately. James M. Whitehurst has been appointed Interim Chief Executive Officer, President and a member of the Board. Roelof Botha, Lead Independent Director of the Unity Board, has been appointed Chairman. Mr. Riccitiello will continue to advise Unity to ensure a smooth transition. The Board will initiate a comprehensive search process, with the assistance of a leading executive search firm, to identify a permanent CEO."

16:22 EDT Xenon: XEN1101 Phase 2b 'X-TOLE' Clinical trial results published - Xenon Pharmaceuticals announced the medical journal JAMA Neurology has published peer-reviewed efficacy and safety results from the X-TOLE Phase 2b randomized clinical trial of XEN1101, a novel potassium channel opener, in adults with focal epilepsy. Importantly, the efficacy and safety findings of this clinical trial supported the further clinical development in epilepsy of XEN1101, which is currently being evaluated in Phase 3 clinical trials in patients with focal onset seizures FOS and primary generalized tonic-clonic seizures. Ian Mortimer, Xenon's President and Chief Executive Officer, stated, "We are pleased to report that the peer-reviewed results from our Phase 2b X-TOLE study of XEN1101 in adults with focal epilepsy have been published in the prestigious JAMA Neurology journal. With a cohort of patients now on drug for more than four years as we continue to gather data from our ongoing open-label extension study, XEN1101 continues to demonstrate its efficacy through sustained seizure reduction and a compelling product profile with once-daily dosing with food and no titration required.

16:15 EDT Brookdale Senior Living reports September occupancy - September 2023 observations: September 2023 weighted average occupancy increased 60 basis points sequentially, from 77.6% in August 2023 to 78.2% in September 2023. Supported by a 130 basis point increase over 2022, September represented 23 consecutive months of year-over-year weighted average occupancy growth. Weighted average occupancy increased sequentially each month within the quarter and the third quarter weighted average occupancy of 77.6% represented 110 basis points of sequential growth compared to the second quarter 2023.

16:11 EDT Integrated Rail and Resources gets extension to consummate combination - The company states: "Pursuant to the Investment Management Trust Agreement between Integrated Rail and Resources Acquisition Corp. and American Stock Transfer & Trust Company, LLC, dated as of November 11, 2021, as amended on February 8, 2023, the Company received notice from the Company's sponsor, DHIP Natural Resources Investments, LLC, at least five days prior to October 15, 2023, that the Company intends to extend the time available in order to consummate a business combination from October 15, 2023 to November 15, 2023. The Company is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any business or industry, it intends to focus its search on natural resources, railroads and/or railroad logistics companies, or any combinations thereof."

16:10 EDT Phaxiam reports very high spectrum of activity its anti-S. aureus phages - Phaxiam Therapeutics announced a very high spectrum of activity of its anti-S. aureus phages against clinical bacterial strains. A retrospective analysis was carried out with 105 clinical Staphylococcus aureus strains which were tested using Phaxiam's phagogram in the context of clinical trials, salvage therapy and early access program (AAC). The results demonstrated that 98% of these pathogenic S. aureus strains were susceptible to at least one of the two Phaxiam's anti-S. aureus phages. Phagogram is an in vitro diagnostic, or IVD, test designed to determine the in-vitro activity of Phaxiam's phages to patients' bacterial strains. Phagogram is the first CE-marked IVD test dedicated to phage activity evaluation.

16:06 EDT Floor & Decor announces grand opening of Albany, NY store - Floor & Decor announced the grand opening of its first store in Albany, New York. Located at 1425 Central Ave. at Colonie Center, it is the first store in the Saratoga County metropolitan area. The warehouse store and design center will open with a team of about 50 full-time and part-time associates led by Luke Langreder, the store Chief Executive Merchant. "We're thrilled to announce our newest store location in Albany," said Langreder. "For more than two decades, Floor & Decor has had the opportunity to serve professionals and homeowners throughout the nation, and we are excited to expand our footprint to Albany with this new location. We look forward to becoming part of the community and welcoming our newest neighbors into our store and making their renovation journeys easier, inspired, and more affordable."

16:05 EDT Fluor receives five-year contract extension for Naval Nuclear Propulsion Program - Fluor Corporation announced that its U.S. Department of Energy's National Nuclear Security Administration contract with Fluor Marine Propulsion, LLC, a Fluor-owned special purpose entity, was extended for five years through 2028. Originally awarded in 2018, the contract had a five-year base period of performance, with a five-year option. Consistent with the original contract, Fluor will recognize all fees earned with this new extension as equity income. The contract supports the Naval Nuclear Propulsion Program that is jointly part of the Department of Energy's NNSA and the Department of the Navy. The scope of the contract includes the management and operation of the Naval Nuclear Laboratory with primary facilities in New York, Pennsylvania and Idaho. "Fluor has supported our nation's security since 1944," said Tom D'Agostino, group president of Fluor's Mission Solutions business segment. "We are proud that the U.S. government continues to place its confidence in us to ensure that the nuclear Navy remains superior and is able to carry out its vital missions anywhere in the world. We look forward to supporting the Naval Nuclear Laboratory as it continues to deliver excellence to the men and women of the Navy who serve our country."

16:03 EDT Veradigm discloses receipt of Nasdaq stay extension - Veradigm "announced that, on October 6, 2023, it received a notice from Nasdaq indicating that the temporary stay of delisting of the Company's common stock has been extended pending a hearing before the Nasdaq Hearings Pane on November 16, 2023, and the issuance of a final Panel decision. Previously, the Company disclosed that, on September 20, 2023, it had received a notice from Nasdaq indicating that the Company's common stock would be delisted due to noncompliance with Nasdaq Listing Rule 5250(c)(1), because the Company did not file its Annual Report on Form 10-K for the year ended December 31, 2022, Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 before the expiration of the 180-day "exception period" that was previously granted by Nasdaq."

15:28 EDT Superior Group appoints Soo-Jin Behrstock as chief information officer - Superior Group announced the appointment of Soo-Jin Behrstock as the company's chief information officer, or CIO, effective immediately. Behrstock, with more than 25 years of broad technology and information systems experience in both business-to-business and e-commerce industries, has an impressive record of strategic thought leadership and transformational implementations. Most recently, Behrstock was the chief information officer at King's Hawaiian.

13:50 EDT GM says latest offer to UAW includes 20% wage increase over life of agreement - General Motors provided an update on what is currently being offered to the UAW, stating that its latest offer includes a 20% wage increase over the life of the agreement with 10% increase in Year 1. The offer also includes reinstatement of COLA for team members at max wages starting Year 2. Reference Link

12:53 EDT Fortress Biotech to effect 1-for-15 reverse stock split - Fortress Biotech announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock. Fortress expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on October 10. The reverse stock split was approved on August 10 by Fortress' board of directors and by Fortress' stockholders at a special meeting held on October 9, with the authorization to determine the final ratio within a specified range having been granted to the company's board. The reverse stock split is intended to bring the company into compliance with Nasdaq's $1.00 per share minimum bid price requirement for continued listing, the company noted.

12:00 EDT Enviva falls -10.7% - Enviva is down -10.7%, or -62c to $5.17.

12:00 EDT Northrop Grumman rises 11.1% - Northrop Grumman is up 11.1%, or $47.15 to $470.39.

12:00 EDT Spruce Power Holding rises 644.2% - Spruce Power Holding is up 644.2%, or $3.59 to $4.14.

11:01 EDT Applied Optoelectronics teases 'something big coming' - Applied Optoelectronics tweeted: "Get ready! We've got something BIG coming your way. Imagine remotely and proactively managing all your system amps! Stay tuned. #QuantumReveal" Reference Link

10:00 EDT Scor ADR falls -6.3% - Scor ADR is down -6.3%, or -$1.23 to $18.20.

10:00 EDT XPeng falls -9.6% - XPeng is down -9.6%, or -$1.75 to $16.41.

10:00 EDT BP Prudhoe Bay rises 11.8% - BP Prudhoe Bay is up 11.8%, or 58c to $5.45.

09:47 EDT XPeng falls -6.6% - XPeng is down -6.6%, or -$1.19 to $16.97.

09:47 EDT Carnival falls -7.4% - Carnival is down -7.4%, or -98c to $12.28.

09:47 EDT Nine Energy Service rises 8.6% - Nine Energy Service is up 8.6%, or 31c to $3.92.

09:41 EDT Fast Acquisition Corp II trading resumes

09:36 EDT Eco Wave Power 'applauds' California governor for signing SB 605 - Eco Wave Power applauds California Governor Gavin Newsom for signing California Senate Bill 605 into law - a historic moment for wave energy in America. The legislation directs the California Energy Commission to evaluate the feasibility of wave and tidal energy in California, including the costs and benefits of implementing the technology across the state's coastline. The California Energy Commission will work with various state agencies and stakeholders to identify suitable locations for wave energy and tidal energy projects in both Californian and federal waters. This comes after California's State Legislature set 2045 as its target for a 100 percent renewable and zero-carbon power grid, with its first benchmark target being 90 percent by 2035. As of 2022, net zero carbon and renewable energy made up 54.23 percent of California's total energy supply. "California leads the way on climate initiatives, and SB 605 further demonstrates the state's leadership across the world," said Eco Wave Power Founder & CEO Inna Braverman. "We believe that wave energy has massive potential, and we will soon be demonstrating our pioneering technology at the Port of Los Angeles and showcasing that wave energy can be a significant force in combating climate change and powering our communities with clean, reliable energy sourced from the endless power of the ocean."

09:25 EDT Diana Shipping announces sale of m/v Boston for $18M - Diana Shipping signed, through a separate wholly-owned subsidiary, a Memorandum of Agreement to sell to an unaffiliated third party, the 2007-built vessel "Boston", with delivery to the buyer latest by December 20, 2023, for a net sale price of approximately $18M.

09:17 EDT EHang announces Nasdaq approval of request to suspend trading of ADSs - EHang Holdings announced that in anticipation of an upcoming announcement concerning a very significant development regarding its business operations, the Company has voluntarily requested the Nasdaq Stock Market to, and the Nasdaq has approved to temporarily suspend the trading of the Company's American depositary shares since the market opens at 9:30 a.m., October 9, 2023, Eastern Time. The Company plans to announce the new development, and make an application with the Nasdaq to resume the trading of its ADSs, no later than 5:00 a.m., October 13, 2023, Eastern Time.

09:13 EDT US Army awards Comtech up to $544M contract for communications/engineering - Comtech announced that it was recently awarded a U.S. Army contract with a maximum ceiling value of $544M. Under the contract, Comtech will provide onsite professional engineering services, as well as supply and support the company's market leading satellite and terrestrial networking communications technologies for the Project Manager Tactical Network for the Global Field Service Representative GFSR support program. The GFSR program provides ongoing communications and IT infrastructure support for the Army, Air Force, Navy, Marine Corps, and NATO-enabling U.S. and coalition forces to maintain robust, resilient, and secure connectivity for global all-domain operations in all environments. "This contract award further demonstrates the differentiated value of our networked communications technologies, as well as the unique, comprehensive domain expertise of our people providing professional engineering services for critical U.S. Department of Defense missions across a comprehensive array of government programs," said Ken Peterman, President and CEO, Comtech. "Comtech's professional engineering services and our extensive portfolio of resilient, blended, smart-enabled networked communications technologies will help the DoD and coalition partners maintain an assured information advantage in an age of Combined Joint All Domain Command and Control operations."

09:09 EDT Volcon formalizes factoring agreement with Prestige Capital Finance - Volcon announced the formalization of a factoring agreement with Prestige Capital Finance. This arrangement provides Volcon with newfound access to cash, enabling the Company to accelerate its growth and meet the expected demand for its revolutionary electric vehicles. Under this new arrangement, Prestige will pay Volcon 80% of the Company's eligible US powersport dealer invoice values immediately, with a maximum fee per invoice of approximately 5% if the invoice is financed over the full 90-day eligibility period. The remaining 20% of the invoice amount, less fees, will be paid to the Company upon collection by Prestige. All invoices factored under this arrangement are full recourse back to the Company in the event of nonpayment. The initial availability under this arrangement will be $6 million and can be increased to support future expected increased sales.

09:07 EDT Fortinet launches FortiSwitch 600, 2000 campus switches - Fortinet announced two new campus switches, the FortiSwitch 600 and 2000. These switches support the growing connectivity and security needs of the campus with high performance, embedded intelligence, and seamless integration with Fortinet's AIOps management tool and FortiGuard AI-Powered Security Services.

09:06 EDT Mullen Automotive appoints Marianne McInerney as CSO - Mullen Automotive announced the appointment of Marianne McInerney as Chief Strategy Officer. In this key role, McInerney will focus on growth opportunities and drive strategic initiatives for Mullen's commercial, consumer vehicles and governmental affairs. Prior to Mullen, McInerney held key roles at next-generation vehicle OEMs, the U.S. Department of Transportation, and the American International Automobile Dealers Association. McInerney served as Assistant Secretary and Director of Public Affairs for the U.S. Department of Transportation under Secretary Elaine Chao. In her role with Mullen, Marianne will focus on sales, marketing and growth opportunities with Mullen's commercial and passenger vehicle programs, and overall strategic business opportunities for the company. She will also oversee all state and federal governmental affairs for the company.

09:05 EDT Life Time Group names WellnessSpace Brands as Official Recovery Partner - WellnessSpace Brands has been named an Official Recovery Partner for Dynamic Personal Training at Life Time. WellnessSpace Brands' products will be included in Life Time locations across North America, expanding WellnessSpace Brands' current imprint. WellnessSpace Brands' products are presently in 30 Life Time locations, with plans to be in the majority of locations by the end of 2024.

09:04 EDT WWE announces record Fastlane event - WWE, part of TKO Group, announced that Fastlane, which emanated from Gainbridge Fieldhouse in Indianapolis, became the most-watched and highest-grossing Fastlane in company history. The live event set new Fastlane records for viewership, gate and sponsorship.

09:03 EDT Hyperfine announces FDA clearance of updated software - Hyperfine announced FDA clearance of updated software. Built on an AI foundation, the latest software brings image quality enhancements to the Swoop system's diffusion-weighted imaging, or DWI, sequence. With this latest software update, Hyperfine, Inc. expands the Swoop system's AI denoising capabilities by incorporating advanced image post-processing into the DWI sequence. The system's other sequences previously benefited from this AI feature. Denoising enables a crisper image that potentially helps clinicians more accurately diagnose, treat, and monitor patients undergoing brain imaging.

09:00 EDT Tigo Energy Inc trading resumes

08:54 EDT Micromobility.com announces uptick in subscriptions - Micromobility.com with Wheels announced a significant uptick in subscriptions following the successful opening of its flagship Soho store. The company is now set to expand its operations into key markets, including Los Angeles, Seattle, Miami, and Austin. In the coming month, Wheels, along with its sister companies Micromobility.com and Helbiz, will transition their existing warehouse locations across the United States into service hubs. This strategic move will not only enhance operational efficiency but also pave the way for these hubs to become subscription center hubs, supporting Wheels' path to profitability as soon as possible.

08:49 EDT Vicinity Motor, ADASTEC to deploy automated transit buses at MSU - Vicinity Motor entered into an agreement to deploy an SAE level-4 vehicle, the Vicinity Autonomous Lightning Electric transit bus, at Michigan State University in conjunction with automated driving software platform provider ADASTEC Corporation. Per the terms of the agreement, the vehicle deployment will take place at the MSU East Lansing Campus in the second quarter of 2024, showcasing Vicinity's next-generation electric transit bus outfitted with ADASTEC's cutting edge automated transportation technology. This landmark initiative is set to be the first of its kind in North America.

08:46 EDT Halliburton, Core Laboratories announce strategic collaboration in U.S. - Halliburton (HAL) and Core Laboratories (CLB) announced a strategic collaboration in the U.S. to compress the delivery time of cutting-edge comprehensive digital rock data solutions from months to weeks, even while full petrophysical laboratory measurements are in progress. This collaboration combines Core Lab's industry-leading expertise in reservoir description and optimization technologies with Halliburton's specialization in pore-scale digital rock analysis. The collaboration facilitates the integration of digital rock characterization at a nano, micro and macro level, which will enable U.S. clients to run pore-scale simulations in parallel with physical laboratory experiments. These enhancements will drive the accuracy and innovation of new and existing digital rock characterization workflows. "Digital rock simulations empower petrophysicists, engineers, and geologists to dynamically evaluate reservoir characterization models while they await the completion of traditional lab measurements, which often takes months," said Chris Tevis, Vice President, Wireline and Perforating, Halliburton. "Our collaboration with Core Laboratories will empower reservoir characterization experts to gain critical insights into their assets much earlier in the assessment process, significantly reducing inherent risks and uncertainties."

08:45 EDT Seaboard announces repurchase of 189,724 shares - Seaboard announced that it has agreed to repurchase 189,724 shares of its common stock, $1.00 par value per share, at a purchase price of $3,162.50 per share. This represents a 15.7% discount to the 180-day volume weighted average trading price of the Common Stock as of October 6, 2023, a 14.9% discount to the 30-day volume weighted average trading price of the Common Stock as of October 6, 2023 and a 13.5% discount to closing price of the Common Stock as of October 6, 2023. The Common Stock will be repurchased for an aggregate purchase price of $600,002,150 from entities affiliated with Ellen S. Bresky, the Chairwoman of the Board of Directors of Seaboard, and other members of the Bresky family, in a privately negotiated transaction. The repurchased shares will be retired.

08:44 EDT Mama's Creations announces planned evolution of senior management team - Mama's Creations announced the planned evolution of the Company's leadership team with two new Vice President of Operations appointments at the Company's East Rutherford and Farmingdale facilities, in conjunction with the retirement of COO Matthew Brown at the end of the third quarter of fiscal 2024. Eric Felice has been promoted to the role of Vice President of Operations, East Rutherford. In addition, Ray Geer has been promoted to the role of Vice President of Operations, Farmingdale. COO Matthew Brown will retire effective October 31, 2023, at which point he will resign from the Board of Directors as well. To ensure a smooth transition, Eric Felice and Ray Geer have already assumed responsibility for operations at their respective facilities for the majority of the third quarter. In conjunction with this announcement and to better enable the operations team to focus on facility-level matters, EVP Steve Burns has broadened his responsibilities as Mama's Creations Chief Administrative Officer. Anthony Morello, President of T&L Creative Salads and Olive Branch, will also broaden his responsibilities to accelerate the Company's efforts to create a "one factory, two locations" approach to operational load sharing and redundancy.

08:42 EDT Tenaya Therapeutics presents clinical, preclinical data on TN-301 program - Tenaya Therapeutics released new data for TN-301 at the 2023 Heart Failure Society of America Annual Scientific Meeting. TN-301 is Tenaya's highly selective small molecule inhibitor of histone deacetylase 6 being developed for the potential treatment of heart failure with preserved ejection fraction. Results from the Phase 1 clinical trial of TN-301 were presented in an ePoster, Phase 1 Clinical Trial Of TN-301, A Highly Selective HDAC6 Inhibitor with Potential in HFpEF, Shows Target Engagement. Tenaya initiated the randomized, double-blind, placebo-controlled Phase 1 clinical trial in September 2022 to assess the safety and tolerability of escalating, oral doses of TN-301, as well as pharmacokinetics and pharmacodynamics measures. The Phase 1 trial enrolled a total of 72 healthy adult participants in two stages. In Stage 1, participants received single ascending doses of either TN-301 at doses ranging from 1mg - 700mg or placebo. Tubulin acetylation was previously established as a relevant PD marker of HDAC6 inhibition in preclinical studies and utilized in the Phase 1 clinical trial to confirm target engagement. Upon achieving evidence of target engagement at single doses of 5mg, participants were enrolled in Stage 2 and received multiple ascending doses of TN-301 at once daily doses of 25mg, 100mg and 300mg for 14 days. Key Findings: TN-301 was generally well tolerated across the broad range of doses studied, with no dose-limiting toxicities or serious adverse events observed. The most common adverse events observed were related to gastrointestinal disturbances. These occurred with similar frequency among those who received placebo or TN-301 and did not increase with TN-301 dose. All participants completed the study. PK results showed overall dose proportionality in both the SAD and MAD stages of the study with a half-life supportive of once-daily dosing. Robust HDAC6 inhibition was observed and increasing doses and exposures with TN-301 correlated with increasing PD effects. Plasma exposure and target engagement observed in this healthy participant study met or exceeded those required for maximal efficacy in preclinical studies. There were no changes in histone acetylation with TN-301, underscoring the selectivity of TN-301 for HDAC6 and potentially reducing the risk of off target effects observed with less selective HDAC6 inhibitors or pan-HDAC inhibition. Future studies of TN-301 in HFpEF patients may evaluate a range of doses starting at approximately 25 mg and higher. The ePoster titled, Co-Administration of Inhibitors of HDAC6 and SGLT2 in Murine HFpEF Models Results in Additive Improvements in Cardiac Structural and Functional Measures, describes an effort by Tenaya researchers to examine the effect of combining TYA-018 with empagliflozin in the company's proprietary HFpEF mouse model. This study compared healthy controls with those treated with TYA-018 and empagliflozin administered alone or in combination vs. untreated HFpEF mice. Key findings: Evidence of additive benefits at or nearing that of healthy controls were observed in all treatment groups at eight weeks, but more substantially with combination treatment, across multiple measures of diastolic function without negative consequences to ejection fraction. At a gene level, an extensive reversal of disease toward healthy controls was observed in TYA-018 and combination groups, but less so in the empagliflozin group. A gene set enrichment analysis of pathway and functional level HFpEF changes provided insights on the distinct impact of HDAC6 inhibition on disease pathophysiology compared to SGLT2 inhibition, with TYA-018 demonstrating a greater impact on improving metabolism, oxidative stress and inflammation.

08:39 EDT EHang Holdings Ltd trading halted, news pending

08:38 EDT Desktop Metal terminates shareholder rights plan amid Stratasys merger cancel - Desktop Metal (DM) announced that, in connection with the termination of the merger agreement between Desktop Metal and Stratasys (SSYS) on September 28, the Desktop Metal board of directors approved the amendment of Desktop Metal's rights agreement, which was previously scheduled to expire on July 24. Pursuant to the amendment, the plan has been terminated as of today. Further details about the amendment to the rights agreement will be contained in a Form 8-K to be filed by Desktop Metal with the SEC.

08:36 EDT Lixte Biotechnology announces passing of founder, executive chairman John Kovach - LIXTE Biotechnology announced the passing of its founder and Executive Chairman, John Kovach, M.D. Kovach, 87, founded the Company in 2005 and held a distinguished medical and scientific career that focused on the causation and treatment of cancer.

08:34 EDT Hepsiburada Card, in partnership with Visa, can now be used worldwide - D-MARKET Electronic Services & Trading (HEPS) announces a five-year agreement with Visa (V) to ensure that the digital prepaid cards of its users are accepted all over the world for online and physical purchases. Users will now be able to create their digital cards with a Visa logo by logging in to their Hepsipay accounts through Hepsiburada. They will be able to top up cash to their Hepsipay cards via transfers from credit or debit cards, as well as transferring cash from their bank accounts. Speaking on the partnership with Visa, Erkin Aydn, CEO of Hepsiburada Financial Services said: "Hepsipay was launched as the platform wallet of Hepsiburada. We are the first and only platform wallet licensed by the Central Bank of the Republic of Turkiye. Hepsipay cards now offer our customers an open loop payment solution. We describe this as expanding Hepsipay to the street. This agreement with Visa serves our goal of expanding our payment solutions outside the Hepsiburada platform and will benefit our customers, allowing them to use their cards at any payment point under the assurance of Visa and Hepsipay. We are excited to be able to benefit from Visa's global experience."

08:33 EDT Allison Transmission teams with B-Metro for 35-foot GILLIG buses - Allison Transmission will partner with B-Metro, the public transit system in Brownsville, Texas, to provide the Allison eGen FlexTM electric hybrid propulsion system for 35-foot GILLIG buses. The city recently received a $4.7M grant from the Federal Transit Administration's FTA 2023 Low or No Emission Program. Brownsville named Allison's eGen Flex electric hybrid technology in its application for the grant. The city is one of 125 communities across the U.S. to be awarded this funding for modernizing bus facilities and purchasing new vehicles that help reduce emissions. "Receiving the FTA grant is a significant win for the city of Brownsville and our residents," said Gennie Garcia, Deputy Director of Multimodal Transportation, City of Brownsville. "The new vehicles will be safer, more reliable and better for the environment. We're eager to update our fleet with fully electric-capable alternatives in order to achieve our goal of reducing carbon emissions."

08:28 EDT Encore Capital announces proposed senior secured floating rates notes offering - Encore Capital Group announced its intention to offer, subject to market and other conditions, EUR 100.0 million aggregate principal amount of its senior secured floating rate notes due 2028 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended and outside the United States to non-U.S. persons. The notes will be issued as "additional notes" under the Company's existing notes indenture dated December 21, 2020, and will have the same terms as the Company's currently outstanding senior secured floating rate notes due 2028. The Notes will bear interest at a rate equal to the sum of three-month EURIBOR plus 4.250% per annum, reset quarterly. The Issuer will pay interest on the Notes quarterly in arrears on January 15, April 15, July 15 and October 15 of each year, commencing on January 15, 2024. The Notes will mature on January 15, 2028. The notes will be senior secured obligations of the Company, and will be fully and unconditionally guaranteed on a senior secured basis by substantially all material subsidiaries of the Company. The obligations of the Company and the guarantors will be secured, together with the Company's other senior secured indebtedness, by substantially all of the assets of the Company and the guarantors. The issue price of the notes will be determined at the pricing of the offering. The Company intends to use the proceeds from this offering to repay drawings under its revolving credit facility, and to pay certain transaction fees and expenses incurred in connection with the offering of the notes.

08:25 EDT Tigo Energy Inc trading halted, news pending

08:22 EDT Ostin Technology secures purchase orders of treadmill screen products - Ostin Technology secured new purchase orders of nearly 5,000 "21.5-inch module" treadmill screen products from a leading fitness equipment manufacturer in China. The Company also unveiled the grand opening of its flagship Douyin store. This exciting launch unveils the M4 and GT8-PRO smartwatches, now available for purchase online.

08:20 EDT Enphase Energy launches home energy systems in Sweden, Denmark - Enphase Energy has entered the solar markets in Sweden and Denmark through an expanded agreement with German-based climate tech startup 1KOMMA5 degrees to offer Enphase Energy Systems, powered by IQ8 Microinverters and IQ Batteries. Enphase and 1KOMMA5 degrees had previously entered into a strategic agreement to extend Enphase's footprint in Germany and other European markets in 2022.

08:19 EDT Lexicon appoints Tom Garner as SVP, CCO - Lexicon Pharmaceuticals (LXRX) announced that Tom Garner is joining the company as senior vice president and chief commercial officer, effective October 9, 2023. In his most recent role, Mr. Garner was the senior vice president and head of the U.S. Cardiovascular and Established Brands business unit at Bristol Myers (BMY).

08:16 EDT National Western Life to be acquired by S. USA Life Insurance for $1.9B - National Western Life announced the signing of a definitive Merger Agreement whereby S. USA Life Insurance Company, an affiliate of Prosperity Life Group, will acquire National Western in an all-cash transaction valued at approximately $1.9B. As part of the agreement, each issued and outstanding share of National Western common stock will be converted into the right to receive $500 in cash at closing of the merger. The merger consideration of $500 per share of National Western's Class A Common Stock and Class B Common Stock represents an 87.1% premium to the unaffected Class A Common Stock share price of $267.29 on May 16, 2023, as well as an 11.8% premium over National Western's 30-day volume-weighted average price as of October 6, 2023. The merger has received the unanimous approval of National Western's Board of Directors. Ross Moody, Chairman of the Board and Chief Executive Officer of National Western, said, "This is an exciting moment in National Western's history. I would like to thank our board of directors, particularly our strategic opportunities committee of independent directors, which conducted a thorough review of a range of strategic alternatives and possible business opportunities to maximize value for our stockholders. The transaction provides clear and immediate value for our stockholders at an attractive premium." The merger is expected to close in the first half of 2024. It is subject to certain customary closing conditions for a transaction of this type, including approval by National Western's stockholders, antitrust clearance and receipt of insurance regulatory approvals.

08:14 EDT Popmenu partners with OpenTable to streamline menu management - Popmenu and OpenTable, part of Booking Holdings, announce a new partnership that "makes it easier than ever for restaurants to tackle one of their most time-consuming headaches: uploading, editing, and managing digital menus," the companies said. Live in the US and Canada today, the partnership will roll out in the UK in early 2024. Shared customers can edit menus via Popmenu or an integrated point of sale system and they will automatically update on OpenTable. The partnership saves operators time and resources, which are valuable commodities for restaurateurs.

08:12 EDT Braemar Hotels & Resorts announces date, time change for Q3 results - Braemar Hotels & Resorts announced that the Company has changed the scheduled date and start time of its third quarter 2023 earnings conference call. The call was previously scheduled for Thursday, November 2, 2023, at 12:00 p.m. ET. Braemar plans to issue its earnings release for the third quarter after the market closes on Thursday, November 9, 2023, and will host a conference call on Friday, November 10, 2023, at 11:00 a.m. ET.

08:11 EDT Itochu, Capital Square announce partnership to acquire build-for-rent community - Capital Square announced the formation of a joint venture partnership with ITOCHU Corporation to acquire Creekside Terrace, a 100-unit build-for-rent single-family community currently being developed by Pulte Homes, the third largest home builder in the country. "We are pleased to partner with Capital Square on Creekside Terrace and look forward to working with Capital Square on future acquisitions," said Hideyuki Matsukawa, senior vice president and general manager of general product and realty division at ITOCHU International Inc.

08:10 EDT National Western Life trading halted, news pending

08:08 EDT Aquestive Therapeutics reaffirms Q4 Anaphylm Phase 3 study start - Aquestive Therapeutics provided a business update on its lead pipeline programs and base business results. The Company recently received comments from the U.S. Food and Drug Administration on its pivotal Phase 3 pharmacokinetic clinical study protocol for Anaphylm Sublingual Film. Anaphylm is a polymer matrix-based epinephrine prodrug administered as a sublingual film that is applied under the tongue for the rapid delivery of epinephrine. Anaphylm comes in a highly portable package with the durability to withstand many of the norms of daily life. In its comments, the FDA indicated that the Company's proposed endpoints, sample size, and statistical analysis are reasonable. As anticipated, the FDA also reminded the Company that PK sustainability post-dosing is an important factor and recommended using repeat-dose data to support PK sustainability. The Company has incorporated the FDA's feedback into its upcoming studies and remains on track to start the pivotal Phase 3 study in the fourth quarter 2023. As previously announced, the Company's NDA for approval of Libervant for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity in patients between two and five years of age was recently accepted for review by the FDA. Diastat Rectal Gel is the only approved treatment currently available to this patient population for this indication. Based on the latest information available to the Company, the review for this NDA remains on track and there are currently no outstanding information requests from the FDA. The NDA for Libervant has a PDUFA assignment date of April 28, 2024. In addition, the Company's base business continues to generate strong results. Based on preliminary third quarter 2023 results and binding supply purchase orders, the Company anticipates increasing current full-year 2023 guidance for revenue and decreasing full-year guidance for non-GAAP-adjusted EBITDA loss. Updated guidance will be provided during the Company's third quarter earnings call in early November.

08:03 EDT Leonardo DRS demonstrates OBVP system in Army evaluation - Leonardo DRS announced that it has demonstrated its On Board Vehicle Power, or OBVP, technology to provide vehicle-based electrical power in support of vehicle-based weapon systems. The OBVP demonstration was part of a recent U.S. Army Operational User Assessment focused on vehicle to vehicle, and vehicle to grid power generation and power management. DRS installed its OBVP systems on the THAAD Launch Control Station FMTV, Tactical Operation Station FMTV, and the THAAD Launcher HEMTT for this assessment. The DRS OBVP system is a vehicle-based generator using a permanent magnet machine integrated within an Allison transmission that provides electrical power to support operations in remote areas. To meet the Army's power needs, OBVP systems are integrated within the vehicle transmission to generate up to 55kW of usable electrical power while on the move, or up to 125kW of usable electrical power while stationary. The DRS OBVP system has proven it can increase battlefield agility, reduce deployment logistics costs, and improve mission readiness with no impact on vehicle functionality.

07:51 EDT Reneo Pharmaceuticals announces last patient last visit in STRIDE study - Reneo Pharmaceuticals announced last patient last visit in the pivotal STRIDE study of mavodelpar in PMM. Topline data results from the STRIDE study are expected in December 2023.

07:38 EDT GigaCloud refutes 'misleading claims' in short seller report - GigaCloud Technology issued the following statement in response to certain claims made in a short seller report issued on September 28, 2023. The company said, "The short seller report questions the feasibility of running the Company's U.S. warehouses and operations with 73 employees, but ignores that the Company utilizes third-party staffing agencies and contractors to support its warehouse operations. The Company has disclosed its use of third-party contractors in the filings made with the Securities and Exchange Commission...The short seller report includes a number of claims regarding the Company's delivery service, but it lacks basic understanding of the Company's business and industry in which it operates. Among other things, the short seller report describes a single instance of a phone call in which a GigaCloud customer service representative allegedly said that the Company uses only GigaCloud trucks for delivery. The Company employs its own trucks predominantly for white glove services in nine metropolitan areas in the U.S. and maintains a dedicated customer service team for such white glove services. GigaCloud customer service representative might have described this white glove service to customers in the context of such delivery, and it should not be misconstrued to suggest that all delivery services are provided in this manner. For other deliveries, including certain last mile deliveries, the Company utilizes a network of third-party delivery providers as disclosed in the filings made with the Securities and Exchange Commission...The short seller report questions the Company's cash balances. KPMG, an independent audit firm registered with the PCAOB, has issued an unqualified opinion on the Company's consolidated financial statements in the Company's annual report on Form 20-F for the year ended December 31, 2022, including the consolidated balance sheets as of December 31, 2021 and 2022 and cash balances presented for the same periods. As of June 30, 2023, the Company's cash balance was $181.5 million...The Company disclosed its related party transaction in accordance with the Form 20-F rules under the Securities Exchange Act of 1934 and applicable accounting standards in the filings made with the Securities and Exchange Commission. The Company reiterates that the conclusions in the short seller report are unsupported and inaccurate. The misleading nature of the statements made in the short seller report demonstrates a fundamental lack of understanding of the Company's business and industry in which it operates. The Company stands by its previous statement that the short seller report lacks merit and contains numerous defamatory and speculative statements. As part of its continued and unwavering commitment to protecting shareholders' interests, maintaining high standards of corporate governance, and providing transparency, the Company's board of directors have authorized the Company to engage a reputable independent third-party to conduct an independent review concerning certain allegations made in the short seller report. The Company will issue further responses once the independent review by the third-party reviewer is completed."

07:36 EDT Accel Entertainment appoints Mark Phelan as president of U.S. gaming - Accel Entertainment announced that Mark Phelan, chief revenue officer, has been appointed to the newly created position of president, U.S. gaming, effective October 6. In this capacity, Phelan will be responsible for setting and guiding Accel's growth strategy, including leading the execution of expansion and diversification initiatives. Phelan will continue to oversee Accel's business development as well as the company's M&A strategy. He will remain an active member of the executive team and continue to report directly to Accel's president and CEO Andy Rubenstein.

07:33 EDT BridgeBio shares long-term data from Phase 2 trial in LGMD2I/R9 - BridgeBio Pharma shared new long-term data from its Phase 2 trial in patients with limb-girdle muscular dystrophy type 2I/R9 at the Annual Congress of World Muscle Societyin Charleston, South Carolina. The new long-term data remains consistent with earlier data from the Phase 2 study showing a well-tolerated safety profile and encouraging preliminary efficacy. Additionally, early changes in glycosylated DG levels at 3 months appear to be associated with ambulatory improvements at 9 months, providing support for the possible use of glycosylated DG levels as a surrogate endpoint in the ongoing Phase 3 study for accelerated approval. BridgeBio presented 21-month results from its ongoing Phase 2 trial, including: Large sustained reduction in creatine kinase observed over an extended treatment period; Stabilization in NSAD scores and ambulatory measures observed over 21-months of BBP-418 treatment; BBP-418 continues to be well-tolerated with longer-term treatment; No treatment-related SAEs or dose limiting toxicities observed with 21-months of BBP-418 dosing. "There is a serious unmet need for those with LGMD2I/R9. The consistent improvement observed in biomarkers as well as stabilization in ambulatory measures are encouraging and help predict the clinical benefit for patients. The data for BBP-418 give me hope that similar results will be carried through in the currently enrolling Phase 3 trial, FORTIFY, for patients with LGMD2I/R9," said Amy Harper, M.D., professor in the department of neurology at Virginia Commonwealth University and primary investigator of the Phase 2 clinical trial in LGMD2I/R9. BridgeBio recently announced the first patient dosed in FORTIFY, its Phase 3 registrational study in patients with LGMD2I/R9 and is continuing to enroll throughout the U.S. with clinical trial sites planned for Europe and Australia. The Phase 3 FORTIFY registrational study is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BBP-418. FORTIFY has a planned interim analysis at 12 months focused on assessing glycosylated alphaDG as a surrogate endpoint to potentially support an accelerated approval. The NSAD and secondary endpoints will be evaluated at 36 months, and results are expected to provide confirmatory clinical data.

07:31 EDT Axon announces FTC has dismissed the antitrust complaint against the company - The Federal Trade Commission, FTC, has dismissed its administrative enforcement action against Axon Enterprise. This action follows Axon's unanimous U.S. Supreme Court victory in April confirming federal court jurisdiction over its constitutional challenges to the FTC's structure-claims the high Court recognized as "existential." "As I said from the beginning, no one should ever face the prospect of a government that can demand to seize your most precious assets without the ability to defend yourself in a fair and impartial court of law," said Axon Founder and CEO Rick Smith. "We made it clear that we were prepared to take the merits of our constitutional claims right back to the Supreme Court, and I'm exceedingly proud of our legal team and the inroads we forged that will now allow others to press these critically important due process and separation of powers issues to ultimate resolution. We at Axon remain laser focused on our mission to protect life."

07:10 EDT Protagonist Therapeutics announces advancement of JNJ-2113 across indications - Protagonist Therapeutics (PTGX) announced that the company will be eligible to receive $60M in milestone payments in the fourth quarter for the advancement of JNJ-2113 into multiple clinical development programs led by Janssen Biotech (JNJ), the Company's partner in the development of JNJ-2113. The ICONIC clinical development program in adult patients with moderate to severe psoriasis is advancing to Phase 3 with two studies starting in November, and the ANTHEM-UC Phase 2b study in adults with moderately to severely active ulcerative colitis will begin this month. The three JNJ-2113 studies that are commencing this quarter include: ICONIC-LEAD - A randomized controlled Phase 3 trial to evaluate the safety and efficacy of JNJ-2113 compared with placebo in participants with moderate to severe plaque psoriasis, with PASI-90 and IGA score of 0 or 1 as co-primary endpoints; ICONIC-TOTAL - A randomized controlled Phase 3 trial to evaluate the efficacy and safety of JNJ-2113 compared with placebo for the treatment of plaque psoriasis in participants with at least moderate severity affecting special areas with overall IGA score of 0 or 1 as the primary end point; and ANTHEM-UC - A Phase 2b randomized controlled trial to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis. Additional Phase 3 studies will be initiated in the first quarter of 2024 as part of the broader psoriasis ICONIC clinical program. All the studies in the ICONIC program will use the once daily, immediate release formulation from the previously completed FRONTIER 1 study. Protagonist will earn a $50 million milestone payment upon dosing of the third patient in the ICONIC Phase 3 program-whichever study meets that milestone first-and a $10 million milestone payment upon dosing of the third patient in the ANTHEM-UC Phase 2b study, and remains eligible for up to an additional $795 million in other development and sales milestone payments with respect to JNJ-2113. The Company will also earn upward tiering royalties of 6%-10%, with the 10% tier applicable for net sales of greater than $4 billion.

07:07 EDT NWTN Inc. announces first NEV Rabdan One marked as 'Made in the Emirates' - NWTN announces that its first new energy vehicle, NEV, Rabdan One, is officially marked as "Made in the Emirates." In August 2023, NWTN attained its own World Manufacturer Identifier, WMI. The WMI is a prerequisite for all original equipment manufacturers for vehicles. In addition to obtaining its WMI, NWTN has also passed the inspection of the Ministry of Industry and Advanced Technology in aid of its "Made in the Emirates" certification process. The "Made in the Emirates" mark was launched by the MoIAT as a new quality mark for UAE-made products. The mark aims to increase consumer confidence in local products. It indicates that products comply with national quality and safety standards, which boosts their competitiveness in international markets.

07:06 EDT Yunji announces receipt of Nasdaq notice - Yunji announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market dated October 5, 2023, indicating that because the closing bid price of the Company's American Depositary Shares for the last 30 consecutive business days was below US$1.00 per share, the Company no longer meets the Nasdaq minimum bid price requirement, set forth in Nasdaq Listing Rule 5450(a)(1). Pursuant to the Nasdaq Listing Rules, the applicable grace period to regain compliance is 180 days, or until April 2, 2024. The Company intends to monitor the closing bid price of its ADSs between now and April 2, 2024 and is considering its options in order to regain compliance with the Nasdaq minimum bid price requirement. The Company can cure this deficiency if the closing bid price of its ADSs is US$1.00 per share or higher for at least ten consecutive business days during the grace period. The Company intends to cure the deficiency within the prescribed grace period.

07:05 EDT Burford Capital announces issuance of new shares in connection with LTIP - Burford Capital Limited announces that, in connection with the Burford Capital 2016 Long Term Incentive Plan, LTIP, it has on October 6, 2023 issued 263,511 new ordinary shares, no par value per share, to satisfy the vesting of restricted stock units pursuant to the realization of awards under the LTIP on October 5, 2023. This issuance of Ordinary Shares was largely offset by the share repurchases announced on September 19, 2023 and completed on September 26, 2023.

07:03 EDT Honeywell receives order for 41 T55-GA-714A engines from U.S. Army - Honeywell announced it has received an order for 41 T55-GA-714A engines to support South Korea's procurement of new CH-47F aircraft as part of an effort to replace its older CH-47D aircraft. The order and supply of the T55 engines is managed through the office of U.S. Army Foreign Military Sales. "We have a longstanding relationship with South Korea, and we appreciate the opportunity to continue supporting them on their new CH-47F Block I Helicopters with our latest T55-GA-714A engine configuration," said Dave Marinick, president, Engines and Power Systems, Honeywell Aerospace. "The latest contract to supply 41 T55 engines is a testament to South Korea's confidence in our battle-proven engines. To date, our T55 engines have logged some 12 million hours of operation on the Boeing CH-47 and MH-47 Chinook helicopters."

07:02 EDT Vitesse sees 2023 production 11,500-11,700 boe/day - With these additional investments and updated timing of well connects, the Company has revised its 2023 guidance and is providing a preliminary outlook for 2024. Vitesse now expects oil and gas production in the fourth quarter of 2023 to average 12,300 to 13,000 Boe per day, up from approximately 11,000 Boe per day in the third quarter of 2023. This results in full year 2023 production ranging from 11,500 to 11,700 Boe per day. Total 2023 capital expenditures are now expected to be $110 to $130 million. The Company's early estimates for 2024 indicate a production range of 12,500 to 13,500 Boe per day and total capital spending, including NTD acquisitions, of $90 to $110 million.

07:01 EDT AerCap announced major business transactions in Q3 - AerCap has announced its major business transactions during the third quarter 2023: Repurchased approximately 20 million shares, at an average price of $58.25 per share, for a total of approximately $1.2 billion. Signed 134 lease agreements, including 24 widebody aircraft, 62 narrowbody aircraft, 25 engines and 23 helicopters. Completed 33 purchases for 19 new aircraft, 9 engines and 5 helicopters. Executed 52 sale transactions for 12 aircraft, 37 engines and 3 helicopters. Signed financing transactions for approximately $3.9 billion.

06:55 EDT Protalix issues statement regarding security situation in Israel - Protalix issued the following statement by Dror Bashan, Protalix's president and CEO, regarding the current security situation in Israel. "The Protalix family is horrified by the unconscionable events in Israel over the past weekend which are currently ongoing and the scope of which is yet to be determined. On a personal level, we are heartbroken and pray for the victims as well as their families, friends and other loved ones. At Protalix, we are dedicated to helping our own families, friends and colleagues cope with this devastating situation and to provide them with any support they need. At the same time, we wish to reaffirm our employees, partners and stockholders that Protalix's operations have not been adversely affected by this situation despite our personal grieving. Hostilities have not taken place where Protalix's facilities are located and we do not anticipate any disruption to the supply of Elfabrio(R) or Elelyso(R). We thank all of our partners and stockholders that have reached out to express their support and best wishes, and are grateful for their continued confidence in Protalix."

06:33 EDT USD Partners announces waiver extension agreement under credit agreement - USD Partners has entered into an agreement with the lenders and administrative agent under its existing Credit Agreement to, among other things, extend the forbearance period as provided in the previously announced amendment to the Credit Agreement, dated as of August 8, 2023, from its original expiration date of October 10, 2023 to November 3, 2023. Pursuant to the Waiver Extension Agreement, the lenders and administrative agent have agreed to continue to forbear until the New Expiration Date from exercising any rights or remedies arising from certain defaults or events of defaults asserted by the administrative agent and to temporarily waive certain events of default arising from the non-payment of interest due on October 10, 2023 until the New Expiration Date.

06:30 EDT TRX Gold announces passing of chairman James Sinclair - TRX Gold Corporation is deeply saddened to announce the passing of its founder and Chairman James Sinclair on October 6, 2023. James founded TRX Gold and acted as Chairman and Director since 2000.

06:08 EDT Krispy Kreme unveils Scooby-Doo Halloween Dozen doughnuts - The company said, "Ruh-Roh! Krispy Kreme (DNUT) and Warner Bros. Discovery Global Consumer Products (WBD), are bringing mystery and monsters to life this Halloween in a first-ever unveiling of the all-new Scooby-Doo Halloween Dozen. Beginning today, fans can head to participating Krispy Kreme shops across the U.S. to grab a Scooby-Doo Halloween Dozen, which comes in a limited-edition custom Scooby-Doo dozens box and features new doughnuts perfect for any event, gathering or adventure this Halloween season."

06:06 EDT GSK, Zhifei announce exclusive strategic vaccine partnership in China - GSK announced that it has reached an exclusive agreement with Chongqing Zhifei Biological Products, Ltd. to co-promote GSK's shingles vaccine, Shingrix, in China for an initial three-year period, with the potential to extend the partnership should all parties agree. Set to start on January 1, 2024, Zhifei will have exclusive rights to import and distribute Shingrix in China - focusing on promoting the vaccine through its service network, which covers more than 30,000 vaccination points across the country. In partnership, GSK - as the license holder for the product - will co-promote Shingrix, the company said. Reference Link

06:02 EDT Best Buy to sell continous glucose monitoring systems - Best Buy will soon offer a convenient way for eligible customers to get prescription continuous glucose monitoring systems delivered right to their home. Facilitated by Wheel and HealthDyne, Best Buy will sell the Dexcom G7 Continuous Glucose Monitoring System to eligible customers through BestBuy.com, where they will be brought to our new platform, Wellness.BestBuyHealth.com to complete the process. Leveraging the Salesforce platform, Best Buy is selling glucose monitors via a site powered by Commerce Cloud. With more CGM system options aimed to come soon after launch, this is the first time the company will offer prescription based medical devices to customers.

05:19 EDT Masimo announces CE mark for Lidco BIC module - Masimo announced the CE mark, under the European Union Medical Device Regulation, for the Lidco board-in-cable, or BIC, module. The Lidco BIC module is designed to connect to multi-patient monitoring platforms, like the Masimo Root Patient Monitoring and Connectivity Hub, to provide advanced hemodynamic monitoring. With this solution, clinicians can easily add Lidco hemodynamic monitoring - with its PulseCO algorithm - to their Root patient monitoring hubs. Like the PulseCO algorithm, the Lidco module is pressure transducer agnostic, maximizing flexibility for clinicians and hospitals. For the first time, there is now a solution that can enable hemodynamic monitoring alongside other supported parameters without having a dedicated hemodynamic monitoring box. The Lidco module supports everything from powerful guided protocols, designed to help assess fluid responsiveness, to rich trending data and notifications for beat-by-beat pressure analysis that can be displayed in the most helpful configurations for each patient on the Root monitor. Combining Masimo rainbow Pulse CO-Oximetry and Lidco hemodynamic monitoring brings the potential for significant new insights into patient status.